A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Abroad (travel likely)RecruitingPHASE2
Conditions
Myelodysplastic Syndromes · Myeloproliferative Chronic Myelomonocytic Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Guillermo Bravo, MD)
Study leads
Guillermo Bravo, MD
Principal Investigator
M.D. Anderson Cancer Center